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Abstract 
Background: This study aimed to investigate the expression of CD147 and MMP-11 in human colorectal cancer 
(CRC) and to evaluate their clinical significance.
Methods: Real-time polymerase chain reaction was used to evaluate CD147 and MMP-11 mRNA level in 56 pairs 
of fresh CRC samples matched with adjacent normal mucosa. The protein expression of CD147 and MMP-11 in CRC 
specimens and corresponding normal colorectal mucosa were evaluated by immunohistochemistry on CRC tissue 
microarrays. Expression and co-localization of these two proteins in human colorectal cancer tissue were also evalu-
ated by laser scanning confocal microscopy. Furthermore, their correlations with clinicopathological factors and 
overall survival after surgery were evaluated.
Results: Both CD147 and MMP-11 were demonstrated to be over-expressed at mRNA level (P < 0.001, both) and 
protein level (P < 0.001, both) in CRC tissue than paired normal mucosa. Spearman rank test showed a positive cor-
relation between these two proteins (P = 0.025). Immunofluorescence double staining confirmed the co-localization 
of CD147 and MMP-11 in paraffin-embedded tissues of CRC patients. Expression of CD147 and MMP-11 were both 
correlated with CRC lymph node metastasis (P = 0.021 and P = 0.031, respectively), distant metastasis (P < 0.001 and 
P = 0.013, respectively) and TNM stage (P = 0.006 and P = 0.049, respectively). Univariate survival analysis showed 
that both CD147 and MMP11 expression was significantly associated with shorter survival time (P = 0.001 and 
P = 0.009, respectively). Additionally, in multivariate analysis, both CD147 and MMP-11 were proved to be independ-
ent prognostic factors (P = 0.009, 0.028, respectively).
Conclusions: These results indicated that both CD147 and MMP-11 may be involved in the progression of colorectal 
cancer, and they are potential prognostic factors and might become new therapeutic targets for CRC patients.
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Background
Colorectal cancer is one of the most prevalent malig-
nant tumors and a main cause of cancer related death 
worldwide. Its incidence has been increasing in China 
in recent years. Although most patients at early stage 
can be successfully cured with surgery, about 20–45  % 
of patients who underwent curative resection devel-
oped recurrence [1]. What’s more, about 15–25 % of all 
CRC patients have a synchronous liver metastasis, of 
which 80–90 % are unresectable [2, 3].Elucidation of the 
malignant biological behavior, especially the metastasis 
mechanism, is expected to bring more benefit to the CRC 
patients in the long run.
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Matrix metalloproteinases (MMPs) are a family of zinc-
dependent endopeptidases that have been extensively 
studied during the past years, and a variety of studies 
have established their crucial roles in the invasion and 
metastasis process of malignant tumors through degra-
dation of the extracellular matrix (ECM) and some other 
mechanisms. MMP-11 (also known as stromelysin-3) is a 
member of the MMPs family. It was originally identified 
as a highly expressed protein in the stromal cells of inva-
sive breast cancer compared to that of fibroadenoma as 
determined by subtractive hybridization [4]. Unlike other 
MMPs, MMP-11 has some unique properties. While 
most MMPs are secreted as inactive zymogens, MMP-11 
is released as a 45  kDa active enzyme [5]. In particular, 
MMP-11 does not appear to degrade any classical extra-
cellular matrix component, instead, it catalyzes the deg-
radation of serine protease inhibitors, a 1-antitrypsin and 
insulin-like growth factor binding protein-1 (IGF-BP-1) 
[6, 7], and it may probably only play an indirect role in 
ECM remodeling, which is different from other MMPs. 
These unique properties indicate that MMP-11 might 
play some unique roles in malignant tumor development 
and progression. Previous studies have investigated its 
role in breast cancer [8, 9] and gastric cancer [10], while 
its role in colorectal cancer has rarely been investigated.
The expression and activity of MMPs are regulated 
under a complex mechanism, which involves a lot of 
signal pathways and related molecules [11], of which 
CD147 plays a key role. CD147, also known as extracel-
lular matrix metalloproteinase inducer (EMMPRIN), is a 
member of the immunoglobulin superfamily of adhesion 
molecules. It plays an essential role in tumor progression 
and metastasis through stimulating tumor cells to secrete 
matrix metalloproteinases (MMPs). The relationship 
between CD147 and MMP-9, MMP-2 and their relevance 
with patients’ prognosis and clinicopathological param-
eters have been studied in a variety of cancers. However, 
the correlation between CD147 and MMP-11 expression 
has rarely been investigated until now.
In the present study, we investigated CD147 and MMP-
11 expression in colorectal cancer. We aimed to make it 
clear the expression level of these two proteins in CRC 
tissue compared with normal mucosa, and their relation-
ship with the clinicopathological parameters and prog-
nosis of the CRC patients, which could provide more 
information for elucidating the molecular mechanism 
and target therapy of the disease.
Methods
Patients and samples
A total of 218 CRC patients who were diagnosed and 
underwent surgery in Peking University Cancer Hospi-
tal between 2006 and 2009 were included in this study. 
Fresh colorectal carcinoma specimens and paired adjacent 
normal mucosa from each patient were formalin-fixed, 
paraffin-embedded, and constructed into tissue microar-
rays. Postoperative follow-up has lasted at least 3 years for 
all of these patients. Patients who received chemotherapy 
or radiation therapy before surgery were excluded. Histo-
pathological evaluation was carried out independently by 
two pathologists. This study was approved by the institu-
tional review board of Peking University Cancer Hospital, 
and written informed consent was acquired from each 
patient. The characteristics of all the patients are shown in 
Table 1.
Quantitative real‑time PCR
Total RNA was extracted from 56 pairs of fresh tissues 
using Trizol reagent (Life Technologies), according to the 
manufacturer’s instructions, and the RNA concentration 
was determined using an Ultrospec® 3300 Pro (GE Health 
Care, Little Chalfont, Buckinghamshire, UK). Reverse 
transcription was performed using 4000 ng of total RNA 
in a 20  μL reaction volume using the EasyScript First-
Strand cDNA Synthesis SuperMix Kit (Life Technolo-
gies). The mRNA expression of CD147 and MMP-11 was 
examined by real-time PCR using Power SYBR® Green 
PCR Master Mix (Life Technologies) with gene-specific 
primers and the ABI 7500 Real-time PCR Detection 
System. The primer sequences were as follows: CD147: 
5′-GGCTGTGAAGTCGTCAGAACAC-3′ (sense) and 
5′-ACCTGCTCTCGGAGCCGTTCA-3′ (antisense); 
MMP-11: 5′-GAGAAGACGGACCTCACCTACA-3′ 
(sense) and 5′-CTCAGTAAAGGTGAGTGGCGTC-3′ 
(antisense); beta-actin: 5′-TTAGTTGCGTTACAC 
CCT TTC-3′ (sense) and 5′-ACCTTCACCAGTTC 
CAGTTT-3′ (antisense). The thermal cycling conditions 
involved predenaturation at 95 °C for 10 min, followed by 
40 cycles of denaturation at 95  °C for 15 s, annealing at 
60 °C for 1 min, and extension at 72 °C for 30 s. All reac-
tions were performed in triplicate. The mRNA expres-
sion was measured using threshold cycle values (Ct). To 
normalize this value, a ΔCt value was determined as the 
difference between the Ct value for each gene and the Ct 
value for β-actin. Then, a ΔΔCt value was determined as 
the difference between the ΔCt value for each individual 
sample and the average ΔCt value for this gene, obtained 
from the control samples. The results were presented as 
fold changes, calculated using the 2−ΔΔCt method (Livak 
and Schmittgen 2001). The comparative Ct method, nor-
malizing Ct values to β-actin, was used to calculate the 
relative expression level of CD147 and MMP-11.
Colorectal cancer tissue microarray (TMA) construction
All specimens were stained with hematoxylin and erosin, 
and matched representative cancerous and adjacent 
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normal mucosa from paraffin blocks were isolated from 
218 colorectal cancer patients. For each patient, three 
cylinders (the diameter is 1.0 mm) of representative can-
cerous paraffin blocks and two cylinders (the diameter is 
1.0 mm) of normal mucosa paraffin blocks were obtained. 
To obtain a broad coverage of the tumor tissue, the three 
regions were preferentially chosen from the tumor center 
and the invasive margins. Then, the representative cyl-
inders were arrayed into a receptor paraffin block by an 
automated tissue-arraying instrument (ALPHELYS) and 
reheated for 30  min at 37  °C. The 4  μm sections were 
then cut from the resulting TMA block.
Immunohistochemistry assay
TMA block sections  (4  μm thick) were baked at 70  °C, 
dewaxed with xylene, and rehydrated with graded 
alcohol washes. Antigen retrieval was performed in a 
pressure cooker, followed by the treatment with 3  % 
hydrogen peroxide for 15 min to block endogenous per-
oxidase activity. Thereafter, the sections were incubated 
at 4  °C overnight with anti-CD147 (ab78106, abcam) or 
anti-MMP-11(ab52904, abcam). The stained specimens 
were exposed to the 3,3-diam-inobenzidine (DAB) Kit 
(Zhong shan Biotechnology Inc., Beijing, China) and 
counterstained with hematoxylin. For the negative con-
trols, primary antibodies were replaced with PBS.
Immunofluorescence assay
Double-fluorescence staining of CD147 and MMP-11 
were conducted on formalin-fixed, paraffin-embedded 
tissue sections from 20 CRC patients. The slides were 
baked at 70 °C, dewaxed with xylene, and rehydrated with 
graded alcohol washes. Antigen retrieval was performed 
in a pressure cooker, followed by the treatment with 3 % 
hydrogen peroxide for 15 min to block endogenous per-
oxidase activity. Thereafter, the sections were incubated 
at 4  °C overnight with anti-CD147 (ab78106, abcam) or 
anti-MMP-11(ab52904, abcam). Then the CD147 and 
MMP-11 primary antibodies were detected by second-
ary antibodies as follows: Goat anti-mouse IgG (Zhong 
shan Biotechnology Inc., Beijing, China, ZF-0312, green) 
and Goat anti-rabbit IgG (Zhong shan Biotechnology 
Inc., Beijing, China, ZF-0316, red). After washing for two 
times, nuclei were stained with 4′,6′- diamidino-2-phe-
nylindole (DAPI, Zhong shan Biotechnology Inc., Beijing, 
China, ZLI-9557) at room temperature for 10  min, and 
stored at 4  °C. The slides were examined using a laser 
scanning confocal microscope (Zeiss LSM510). Images 
were collected and processed using the Zeiss AIM soft-
ware and sized in Adobe Photoshop CS6.
Evaluation immunohistochemical of staining
The CD147 and MMP-11 staining were microscopi-
cally examined and scored by two independent patholo-
gists who were blind to the clinical data pertaining to the 
patients. For CD147 and MMP-11 immunohistochemical 
staining assessment, immunoreactivity score (IRS) was 
assessed which evaluated both the percentage of positive 
cells and the staining intensity. The percentage of positive 
cells was scored as 0 (negative), 1 (<25 %), 2 (25–75 %), 
and 3 (>75 %); staining intensity was graded as 0 (color-
less), 1 (pallide-flavens), 2 (yellow), and 3 (brown). The 
above two scores were multiplied, and “negative” and 
“positive” expression were defined according to IRS val-
ues of 0 and >0, respectively.
Statistical analysis
Statistical analysis was carried out using SPSS software 
package version 16.0 (SPSS Inc., Chicago, IL, USA). The 
differential expression of CD147 and MMP-11 mRNA 
between colorectal cancer tissues and adjacent nor-
mal mucosa was compared using a nonparametric test. 
Two-tailed χ2 test was used to evaluate the expression 
difference between colorectal cancer tissue and normal 
Table 1 Summary of patient characteristics (n = 218)
Clinicopathological features No. of patients (%) of patients
Gender
 Male 129 59.17
 Female 89 40.83
Age
 <60 99 45.41
 ≥60 119 54.59
Tumor size (cm)
 <4 104 47.71
 ≥4 114 52.29
Lymphovascular invasion
 Absent 149 68.35
 Present 69 31.65
Differentiation
 Well-moderate 179 82.11
 Poor 39 17.89
Depth of invasion
 T1 + T2 33 15.14
 T3 + T4 185 84.86
Lymph node metastasis
 N0 89 40.83
 N1–2 129 59.17
Liver metastasis
 M0 106 48.62
 M1 112 51.38
TNM stage
 I + II 75 34.40
 III + IV 143 65.60
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mucosa, as well as the relationship between the clinico-
pathological features and CD147 or MMP-11 expression. 
Correlation between CD147 and MMP-11was evaluated 
using the Spearman rank test. The survival curves were 
estimated by Kaplan–Meier analysis, and P values were 
calculated by log rank test. The effect of different factors 
on patient survival was performed by multivariate analy-
sis with the Cox proportional hazards regression model. 
P < 0.05 was considered significant.
Results
mRNA expression of CD147 and MMP‑11 in fresh, paired 
CRC tissues
Both CD147 and MMP-11 mRNA expression levels in 56 
pairs of primary CRC and matched normal mucosa were 
examined using real-time PCR. Results showed that the 
mRNA levels of both CD147 and MMP-11 were much 
higher in tumor tissues than in normal tissues (P < 0.001, 
both) (Fig. 1).
CD147 and MMP‑11 expression in CRC tissues by IHC 
and immunofluorescence double staining
Immunohistochemical staining showed a membranous 
and cytoplasmic staining of both CD147 and MMP-11 of 
tumor cells (Fig. 2). CD147 expression in normal mucosa 
was significantly lower than that in colorectal cancer 
(9.17 vs. 59.63  %, P  <  0.001). Similarly, there was also a 
significantly higher expression of MMP-11 in colorectal 
cancer tissue than in normal mucosa (77.06 vs. 33.94 %, 
P < 0.001) (see Table 2). Spearman’s rank correlation coef-
ficient test showed a positive correlation between CD147 
and MMP-11 expression in CRC tissues (rs  =  0.152, 
P  =  0.025). Immunofluorescence double staining assay 
confirmed the intracellular localization of CD147 and 
MMP-11 shown in immunohistochemical staining, and 
evident co-localization can be observed between these 
two proteins (Fig. 3).
Association of immunohistochemical expression of CD147 
and MMP‑11 with clinicopathological features
Based on staining evaluation and the statistical analy-
sis, we further investigated the correlation between 
CD147/MMP-11 expression and the clinicopathologi-
cal features as shown in Table 3. CD147 expression was 
markedly higher in patients with lymph node metastasis 
(P = 0.021), distant metastasis (P < 0.001), and advanced 
TNM stage (P =  0.006). Interestingly, MMP-11 expres-
sion was also significantly correlated with the above three 
parameters, with P  =  0.031, 0.013, 0.049, respectively. 
However, both CD147 and MMP-11 expression was 
not correlated with patient’s gender, age, differentiation, 
tumor size, and depth of invasion. Detailed results are 
shown in Table 3.
Prognostic implication of CD147 and MMP‑11 in colorectal 
cancer
The follow-up time of all patients was from February 
2006 to July 2014. The overall median survival time was 
49.35 months. During the follow-up period, a total of 79 
patients died of colorectal cancer. The survival curves 
were estimated by Kaplan–Meier analysis and then 
compared using the log-rank test. Results showed that 
patients with CD147 or MMP-11 expression had a poorer 
prognosis (P = 0.001 and 0.009, respectively) (Fig. 4). To 
test the prognostic value of combined expression status 
of CD147 and MMP-11, we classified all patients into two 
groups, CD147+/MMP-11+ group and all other expres-
sion statuses as the other group. Kaplan–Meier analy-
sis showed that patients with CD147+/MMP-11+ had 
a significantly poor survival time than those with other 
Fig. 1 Real-time PCR evaluation of CD147 and MMP-11 mRNA expression in 14 pairs of CRC tissues and matched normal mucosa. a mRNA expres-
sion of CD147 in tumor tissues was higher than that in normal tissues (P = 0.002). b mRNA expression of MMP-11 in tumor tissues was higher than 
that in normal tissues, too (P = 0.043). The relative quantification (RQ) was calculated using the 2−ΔΔCtmethod
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expression statuses (P  =  0.002). Then, to test whether 
CD147 and MMP-11 expression were independent prog-
nostic factors for CRC patients, we performed a mul-
tivariate survival analysis, in which those parameters 
associated with overall survival in the univariate survival 
analysis were included. In univariate analysis, CD147 
expression (P = 0.001), MMP-11 expression (P = 0.011), 
differentiation (P  <  0.001), lymphovascular invasion 
(P < 0.001), and tumor staging (P < 0.001) were associated 
with overall survival. In multivariate analysis lymphovas-
cular invasion, CD147, MMP11 and tumor staging were 
independent prognostic factors related to overall survival 
(P  =  0.044, 0.009, 0.028, <0.001, respectively). Detailed 
data are shown in Table 4. 
Discussion
Local invasion and distant metastasis are suggested to 
be the key reasons for poor prognosis and cancer related 
death in tumor patients. Both these two proteins inves-
tigated in this study are closely related with tumor inva-
sion and metastasis. In this study we found that there 
was an increased expression of CD147 and MMP-11 in 
Fig. 2 Representative immunohistochemical staining of CD147 and MMP-11 in CRC tissue and matched normal mucosa. a, b show CD147 staining 
in normal mucosa and CRC tissue, respectively (magnification ×100). c, d show MMP-11 staining in normal mucosa and CRC tissue, respectively 
(magnification ×100). As is shown, CD147 protein is predominantly localized on cell membrane and in the cytoplasm, while MMP-11 protein was of 
cytoplasmic staining
Table 2 Expression of CD147 and MMP-11 in carcinoma tissue and matched normal mucosa of CRC patients
Groups CD147 expression MMP‑11 expression
Positive (%) Negative (%) P value Positive (%) Negative (%) P value
Carcinoma tissue 135 (61.93) 83 (38.07) <0.001 168 (77.06) 50 (22.94) <0.001
Normal mucosa 21 (9.63) 197 (90.37) 74 (33.94) 144 (66.06)
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colorectal cancer compared with paired normal mucosa, 
suggesting that CD147 and MMP-11 might play an onco-
genic role in colorectal cancer.
It has been well documented that CD147 induces the 
expression of several MMPs, such as MMP-1, MMP-2, 
MMP-9 [12], which are associated with tumor migration 
and invasion. The mechanisms by which CD147 up-regu-
lates MMPs family appear to depend on its stimulation of 
the tumor-associated fibroblasts. The expression associa-
tion between CD147 and MMP-2, MMP-9 has been well 
established in a series of human malignant tumors, such 
as gallbladder carcinoma, thyroid carcinoma, breast can-
cer, gastric cancer and colorectal cancer. While up to now, 
reports on the relationship between CD147 and MMP-11 
are limited. Jia et al. reported that in murine hepatocarci-
noma Hca-F cells, depletion or deglycosylation of CD147 
down-regulated MMP-11 expression [13]. In another 
study, knockdown of CD147 reduced the secretion of 
MMP-11 in nasopharyngeal carcinoma [14]. In our study, 
we explored the relationship between CD147 and MMP-
11 expression in colorectal cancer, and found a positive 
correlation between these two proteins, and immuno-
fluorescence double staining showed co-localization of 
these two proteins, which has provided new evidence for 
the regulatory interaction between CD147 and MMP-11.
Recent studies have established a role of oncogenic and 
tumor promoter for CD147, and its expression has been 
proved to be related with clinicopathological characteris-
tics in a variety of cancer types. Zhong et al. [15] found that 
CD147 expression was correlated with higher incidence of 
lymph node metastasis and lower differentiation in stage 
T1 pulmonary adenocarcinoma; Zhao et  al. [16] found 
Fig. 3 Representative photomicrographs of double fluorescent staining of CD147 with MMP-11. Both a CD147 (green) and b MMP-11 (red) showed 
a predominant membranous and cytoplasmic localization. c DAPI (blue) was stained to identify nuclei. d Co-localization of CD147 and MMP-11 (yel-
low) is apparent. Scale bar 20 µm
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that CD147 expression was correlated with tumor invasion 
and metastasis in triple-negative breast cancer; in human 
astrocytomas and meningiomas, overexpression of CD147 
was found in high-grade tumors, and it was positively 
correlated with WHO grades [17]. What’s more, CD147 
expression has always been associated with a poor survival 
of cancer patients [18, 19]. As for colorectal carcinoma, 
previous studies have got similar results. Zheng et al. [20] 
found that CD147 protein was up-regulated in colorectal 
cancer, without the alteration of its glycosylation or mRNA 
level. Stenzinger showed in their study that CD147 expres-
sion was associated with clinical TNM stage of CRC [21]. 
A recent study showed that CD147 was an independent 
prognostic factor for disease-free survival of CRC patients 
[22]. In our study, we have found that CD147 expression 
was correlated with lymph node metastasis, distant metas-
tasis, as well as TNM stage for CRC; What’s more, it is 
an independent prognostic factor for CRC patients. Our 
results have highlighted the important role of CD147 in 
the metastasis of CRC and its prognostic value in patients, 
both of which suggesting its clinical significance. Recently, 
some novel roles of CD147 in cancer have also been found. 
Xu et al. [23] uncovered a role of CD147 in transforming 
fibroblasts to cancer-associated fibroblasts, which in turn 
induced epithelial-to-mesenchymal (EMT) transition of 
breast cancer cells. These findings support a novel role of 
CD147 in regulating the interaction between cancer and 
stroma. Hibino et al. [24] found that the calcium-binding 
proteins S100A9 may serve as a novel ligand for CD147 to 
promote melanoma metastasis. ERK1/2 signaling pathway 
was found to be involved in CD147-mediated proliferation 
and invasion of gastric cancer cell line SGC7901 [25]. In 
another study, hypoxic microenvironment was postulated 
to be a major initiator of the overexpression of CD147 
[26]. In addition, it has been reported that CD147 might 
be involved in drug resistance in different cancer types, via 
different mechanisms [22, 27]. The above discoveries sug-
gested that CD147 can be involved in several malignant 
transformation processes other than inducing MMPs, and 
it may exert its function as a member in networks, instead 
Table 3 Association of CD147 and MMP-11 expression with clinicopathological features
Clinicopathological features CD147 expression MMP‑11 expression
Positive (%) Negative (%) P value Positive (%) Negative (%) P value
Gender
 Male 83 (64.34) 46 (35.66) 0.377 99 (76.74) 30 (23.26) 0.892
 Female 52 (58.43) 37 (41.57) 69 (77.53) 20 (22.47)
Age (years)
 <60 57 (57.58) 42 (42.42) 0.228 77 (77.78) 22 (22.22) 0.819
 ≥60 78 (65.53) 41 (34.45) 91 (76.47) 28 (23.53)
Differentiation
 Poor 26 (66.67) 13 (33.33) 0.501 32 (82.05) 7 (17.95) 0.414
 Moderate-well 109 (60.89) 70 (39.11) 136 (75.98) 43 (24.02)
Size
 <4 cm 62 (59.62) 42 (40.38) 0.502 81 (77.88) 23 (22.12) 0.783
 ≥4 cm 73 (64.04) 41 (35.96) 87 (76.32) 27 (23.68)
Lymphovascular invasion
 Absent 93 (62.42) 56 (37.58) 0.827 110 (73.83) 39 (26.17) 0.095
 Present 42 (60.87) 27 (39.13) 58 (84.06) 11 (15.94)
Depth of invasion
 T1/T2 16 (48.48) 17 (51.52) 0.084 22 (66.67) 11 (33.33) 0.123
 T3/T4 119 (64.32) 66 (35.68) 146 (78.92) 39 (21.08)
Lymph node metastasis
 N0 47 (52.81) 42 (47.19) 0.021 62 (69.66) 27 (30.34) 0.031
 N1–2 88 (68.22) 41 (31.78) 106 (82.18) 23 (17.83)
Distant metastasis
 M0 53 (63.86) 30 (36.14) <0.001 74 (69.81) 32 (30.19) 0.013
 M1 53 (39.26) 82 (60.74) 94 (83.93) 18 (16.07)
TNM stage
 I + II 37 (49.33) 38 (50.67) 0.006 52 (69.33) 23 (30.67) 0.049
 III + IV 98 (68.53) 45 (31.47) 116 (81.11) 27 (18.89)
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Fig. 4 Kaplan–Meier overall survival analysis of colorectal cancer patients. Survival analysis was performed according to the expression status of a 
CD147 (P = 0.001), b MMP-11 (P = 0.009), and c CD147 combined with MMP-11 (P = 0.002), respectively
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of a dominant sector, maybe that’s why discrepancies exist 
in different studies.
As a member of the MMPs family, MMP-11 has long 
been postulated to play an important role in tumorigenesis, 
invasion, metastasis and poor clinical outcome in malig-
nant tumors. While owing to its complex biological prop-
erty, the role of MMP-11 has not been that established as 
other MMPs, such as MMP-2 and MMP-9. The mechanism 
by which MMP-11 participates in tumor progression is also 
unique. On the one hand, it belongs to the MMPs family, 
so it possesses some common properties of the family; on 
the other hand, it is devoid of enzymatic activity against 
the matrix components which is thought to be the most 
prominent feature of the family, so it may not have that 
much power in paving the path for tumor cells during their 
migration and invasion into the healthy tissue effectively 
just like other MMPs. In a study conducted by Boulay et al. 
[28], a new and unexpected role for MMP was revealed, 
that is, tumorigenesis induced by MMP-11 does not result 
from increased neo-angiogenesis or cancer cell prolifera-
tion, but from decreased cancer cell death through apop-
tosis and necrosis, indicating that the cellular function of 
MMP-11 is to favor cancer cell survival in the stromal envi-
ronment. Similarly, MMP-11may also play a role in lobular 
carcinogenesis through increasing resistance to anoikis [9]. 
Recently a study reported the relationship between MMP-
11 and inflammation. MMP-11 expression by mononuclear 
inflammatory cells (MICs) coupled with the expression of 
pro-inflammatory proteins support tumor escape and inva-
sion, hence promoting metastasis, so they claim that the 
expression of MMP-11 may constitute a useful biological 
marker for pro-metastatic MICs [29].
Interestingly, there might also be a dual role of MMP-
11 in cancers. It plays an oncogenic role in cervical cancer 
[30] and gastric cancer [31]. It can also serve as a predic-
tor of prognosis, overexpression of MMP-11 was associ-
ated with poor prognosis in breast ductal carcinoma [8] 
and advanced gastric cancer [10]. In our study, it is sig-
nificantly related with survival of CRC patients and can 
also serve as an independent prognostic factor in multi-
variate analysis; what’s more, MMP-11 was associated 
with lymph node metastasis and distant metastasis, and 
also with tumor’s TNM stage, which was similar with 
results in non-small cell lung cancer and breast cancer 
[32, 33]. However, Brasse et  al. [34] found a paradoxical 
role of MMP-11 during the hematogenous metastatic 
process in mice. In their research, MMP-11 favors the 
onset and growth of lung metastasis but limiting lung foci 
number, and inhibiting the cancer cell dissemination to 
other organs. In another study, there was an inverse rela-
tionship between MMP-11 expression and predictors of 
poor prognosis of papillary thyroid carcinoma [35]. All 
the reported results indicated a multidimensional role of 
MMP 11 in cancer. If this is also the situation with other 
MMPs, although it’s just a bold presume without enough 
evidence up to date, maybe the dismal curative effect of 
the anti-MMPs new drugs can be explained. Studies 
with more cases and more functional investigation are 
necessary.
Conclusions
Our study has demonstrated that CD147 and MMP-11 
are overexpressed in colorectal cancer, and there’s a posi-
tive correlation and co-localization between these two 
Table 4 Cox proportional hazard regression model analysis
Variables Univariate Cox’s regression analysis Multivariate Cox’s regression analysis
Relative risk 95 % CI P value Relative risk 95 % CI P value
Differentiation
 Moderate-well versus poor 0.397 0.244–0.646 <0.001
Lymphovascular invasion
 Present versus absent 3.606 2.310–5.627 <0.001 1.611 1.013–2.561 0.044
CD147 expression
 Positive versus negative 2.364 1.422–3.931 0.001 2.023 1.193–3.430 0.009
MMP-11 expression
 Positive versus negative 2.281 1.206–4.316 0.011 2.094 1.083–4.047 0.028
T stage
 T1 + T2 versus T3 + T4 4.432 1.619–12.132 0.004
N stage
 N0 versus N1 + N2 + N3 6.616 3.486–12.556 <0.001
Metastasis
 No versus yes 32.746 12.946–82.860 <0.001 25.970 10.001–67.442 <0.001
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proteins. Both CD147 and MMP-11 might act as tumor 
promoters during the progression of CRC patients. 
What’s more, the two proteins are associated with 
patients’ survival. These indicated that CD147 and MMP-
11 might become potential prognostic markers as well as 
therapeutic targets for CRC patients.
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